Clinical Trial Update: A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sacituzumab govitecan in combination with cetuximab for head and neck squamous cell cancers is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasal Cavity Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Sinonasal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Tukysa (tucatinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Status: RECRUITING